PHE News

Precision's Experts Coming to Denver for AMCP 2017!

The AMCP 2017 Annual Meeting is fast approaching-- it will be held in Denver March 27-30th! Precision is looking forward to showing off our capabilities and experts with an impressive presence. Don't miss the chance to be there!

READ MORE

"Value of Hope" Study by PHE Authors Published in Value in Health Special Issue

The study be PHE authors Jason Shafrin, Taylor Schwartz, and John Romley is featured in a special issue of Value in Health, focusing on value framework assessments.

READ MORE

Shafrin in eyeforpharma: Value-based Pricing’s Time Has Come, and It’s Here to Stay

PHE Senior Research Economist Jason Shafrin talks prices, politics, and the problem of monopolies with eyeforpharma’s Hugh Gosling.

READ MORE

Neumann Discusses Cures Act and New FDA Draft Guidance on Communication

Provisions of the 21st Century Cures Act and new FDA draft guidance suggest greater flexibility for drug companies in the communication of the real-world drug impacts of their products.

READ MORE

PHE Team Releases New Study on Medicare Part D Price Controls

Authors Moreno, van Eijndhoven, Benner and Sullivan examine the potential impact over time of government price settings for prescription drugs.

READ MORE

Peter Neumann in New England Journal of Medicine: Cost-Effectiveness 2.0 -- Poised for a Second Act?

PHE Scientific Advisor Peter Neumann offers a new perspective on cost-effectiveness analysis in the New England Journal of Medicine.

READ MORE
 
  • Academic Insights at

    the Speed of Business

     
  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

     
  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

     
  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

     
  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Value, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

     
  • Academic Insights at

    the Speed of Business